Moreover, treatment of B-RafV600-mutant melanoma using a B-Raf inhibitor or its combination with a MEK inhibitor typically elicits only partial responses due to the tumor cell-intrinsic reprogramming that attenuates the MAPK dependency [18]. This evidence concerns the gene BRAF and neoplasm.